^
    Back
    Association details:
    Biomarker:HR negative
    Cancer:HER2 Negative Breast Cancer
    Drug:ganitumab (AMG 479) (IGF-1R inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Nature
    Title:

    Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

    Published date:
    10/05/2021
    Excerpt:
    Ganitumab was tested in combination with metformin and paclitaxel (PGM)...In the HR-negative/HER2-negative subtype, pCR rates were higher in the arm compared to control…
    Secondary therapy:
    paclitaxel + metformin
    DOI:
    https://doi.org/10.1038/s41523-021-00337-2